Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
LAVA-CRLM: SBRT vs MWA 1-yr FFLP 83.0% vs 77.7% (HR 0.87, p=0.70), acute G2+ toxicity 3% vs 25% in 1-3 oligometastatic CRLM.
Oligo-mets carried the day. In a randomised phase II, SBRT (45 Gy/3 fx, 88% MR-linac adaptive) showed no local control difference vs MWA for small CRLM, with less early toxicity. It was powered for HR 0.38, not equivalence, and median lesion size was 1.2 cm. Intermediate-size lesions await COLLISION-XL.
read the full digest →Studies · 135
- LAVA-CRLM1-yr freedom from local progression 83.0% SBRT vs 77.7% MWA (HR 0.87, p=0.70); treatment-related G2+ toxicity 3% vs 25% in oligometastatic CRLM.
- ROAM/EORTC-1308Adjuvant IMRT 60 Gy/30 fx vs observation after complete resection of WHO grade 2 atypical meningioma: DFS HR 0.51 (0.27–0.97); 5-yr DFS 79.9% vs 64.3%.
- BIG 3-07/TROG 07.01Tumour bed boost after WBI in resected non-low-risk DCIS: 5-yr freedom from LR 97.1% vs 92.7%, HR 0.47 (0.31-0.72), p<0.001.
- TRT in Prostate Cancer Survivors (Bhasin RCT)Sexual activity +0.91 daily events vs placebo (95% CI 0.56-1.26, P<.001) with 12wk testosterone; zero biochemical recurrences in low-grade post-RP hypogonadal men.
- ASTRO Clinical Practice Guideline: RT for Bladder CancerTMT recommended (strong, high QoE) as alternative to RC for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
- Gamma Knife vs LINAC-based radiosurgery for vestibular schwannoma (retrospective review)Local control 98.8%; no difference in new vertigo, gait disturbance or facial palsy with GKRS (n=36) vs LINAC (n=49) SRS for vestibular schwannoma.
- SWOG S1827/MAVERICKRandomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.
- TORPEdO18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).